Abstract
Background
Hepatocellular cancer (HCC), as well as cholangiocellular cancer (CCC), has an extremely poor prognosis due to the extent of tumor at diagnosis and the underlying liver disease. Sirolimus is used in the transplantation setting as an immunosuppressive agent, but it also possesses antiproliferative and antiangiogenic properties. The objective of the study was to evaluate the effect of sirolimus on HCC and CCC.
Methods
In a prospective single-arm protocol, the tumor response to sirolimus as the primary endpoint was studied in 21 patients with advanced HCC and nine with CCC. Sirolimus was administered once daily by mouth, with the dose adjusted to a serum trough level between 4 and 15 μg/ml. Tumor response was evaluated by computed tomography (CT) or magnetic resonance imaging (MRI), according to the Response Evaluation Criteria in Solid Tumors (RECIST), every third month. Secondary measures were overall survival, time to tumor progression, tumor markers, and side effects.
Results
Of the patients with HCC, one had partial remission (PR) and fi ve patients had stable disease (SD) at 3 months. Of the patients with CCC, three had SD. The median survival for patients with HCC was 6.5 months (range, 0.2–36 months) and that for patients with CCC was 7 months (range, 2.6–35 months).
Conclusion
Treatment of HCC and CCC with sirolimus can induce temporary PD or SD. This pilot study indicates that sirolimus might be a promising drug for this treatment, but further clinical studies elucidating the biological effects are advocated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Llovet JM, Bruix J (2004) Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization (letter). Radiology 230: 300–302
Neuhaus P, Klupp J, Langrehr J (2001) mTOR inhibitors: an overview. Liver Transpl 7:473–484
Ogawa T, Tokuda M, Tomizawa K, et al. (1998) Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteo-sarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun 249:226–230
Hosoi H, Dilling MB, Shikata T, et al. (1999) Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59:886–894
Schumacher G, Oidtmann M, Rosewicz S, et al. (2002) Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus, which promotes cell growth. Transplant Proc 34:1392–1393
Schumacher G, Oidtmann M, Rueggeberg A. (2005) Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11:1420–1425
Kim DH, Sarbassov DD, Ali SM, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–175
Guba M, von Breitenbuch P, Steinbauer M, et al. (2002) Rapamycin inhibits primary and metastatic tumour growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135
Rizell M, Lindner P (2005) Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res 25:789–793
Roskamps T (2006) Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25:3818–3822
Guba M, Koehl GE, Neppl E, et al. (2005) Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18:89–94
Franz DN, Leonard J, Tudor C, et al. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498
Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
Therasse P, Eisenhauer EA, Verweij J. (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031–1039
Ratain MJ, Eckhardt G. (2004) Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 22:4442–4445
National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 3.0 Published date June 10, 2003, Ncl, Rockville
Rizell M, Cahlin C, Friman S, et al.(2005) Impressive regression of primary liver cancer after treatment with sirolimus. Acta Oncol 44:496
Xu X, Kobayashi S, Qiao W, et al.(2006) Induction of intrahepatic cholangiocellular carcinom by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116:1843–1852
Sahin F, Kannangai R, Adegbola O, et al. (2004) mTor and p70 s6 kinase expression in primary liver neoplasms. Clin Cancer Res 10:8421–8425
Torimura T, Sata M, Ueno T, et al. (1998) Increased expression of vascular endothelial growth factor is associated with tumour progression in hepatocellular carcinoma. Hum Pathol 29:986–991
Wang T E, Kao C R, Chen L T, et al. (2004) Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 10:649–653
Schwartz J D, Schwartz M, Goldman D, et al. (2005) Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 23:412
Kneteman NM, Oberholzer J, Al Saghier M, et al. (2004) Sirolimusbased immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10:1301–1311
Author information
Authors and Affiliations
Corresponding author
Additional information
All authors contributed to the conception of the study, analysis of data, and writing of the communication
About this article
Cite this article
Rizell, M., Andersson, M., Cahlin, C. et al. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 13, 66–70 (2008). https://doi.org/10.1007/s10147-007-0733-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-007-0733-3